

# ASX Release

**SUDA LTD**

## Change of Name to Suda Ltd and ASX code to SUD

At the recent AGM, shareholders had agreed to change the name from Eastland Medical Systems Ltd to Suda Ltd. We have now received formal notice of the change of name from ASIC and the new ASX code is **SUD**.

Under the name of Eastland, we often had feedback that we were the needle technology company. This was the basis of the business several years ago but the business of today is very different. As we launch the Company into a new phase of growth, we believed it important to leave the old Company behind and give your Company a new name, a new logo and a new structure.

The word "Suda" is a reference to an ancient encyclopedia. The Directors believe that it is an appropriate name for a company whose value and strength is derived from the generation of new knowledge and intellectual property.

The new logo is as above.

### Growth of the business

We have engaged a European consultant who has many years' experience in the pharmaceutical industry and has already identified various opportunities for our consideration. We will continue to explore opportunities to develop and/or acquire other projects into the commercialisation pipeline. The Company has been reliant primarily on the ArTiMist™ project and it is now an appropriate time to look to expand the operations.



### Further information:

Stephen Carter  
Executive Chairman  
Director  
Suda Ltd  
Tel: +61 8 6142 5555  
[sjcarter@eastlandmedical.com.au](mailto:sjcarter@eastlandmedical.com.au)

## **Suda Ltd**

Suda Ltd (ASX:SUD) is an Australian pharmaceutical company commercialising low-risk pharmaceutical projects. Our lead product ArTiMist™, a sub-lingual artemether based malaria treatment, has been developed specifically for children with severe malaria. ArTiMist™ is currently in Phase III clinical trials in Africa.

ArTiMist™ treatment is administered sub-lingually and enters the bloodstream where the parasite lives, attacking at a far greater speed than conventional tablets and reducing the need for continued hospitalisation whilst presenting significant cost savings to governments and relief organisations. ArTiMist™ is especially effective in the treatment of children and young infants who are experiencing malaria-related and gastro-intestinal problems and cannot tolerate tablet treatments.